Skip to Content

UCB SA UCBJF

Morningstar Rating
$128.73 +2.68 (2.12%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

Price
$128.71
Fair Value
$831.26
Uncertainty
High
1-Star Price
$961.57
5-Star Price
$341.43
Economic Moat
Dfjg
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if UCBJF is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$126.05
Day Range
$128.73128.73
52-Week Range
$69.70128.73
Bid/Ask
$126.20 / $135.65
Market Cap
$24.43 Bil
Volume/Avg
376 / 423

Key Statistics

Price/Earnings (Normalized)
25.05
Price/Sales
4.33
Dividend Yield (Trailing)
1.06%
Dividend Yield (Forward)
1.17%
Total Yield
1.21%

Company Profile

UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), and Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome).
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Large Growth
Total Number of Employees
9,083

Competitors

Valuation

Metric
UCBJF
EXEL
JAZZ
Price/Earnings (Normalized)
25.0525.395.94
Price/Book Value
2.413.061.81
Price/Sales
4.334.022.05
Price/Cash Flow
24.8221.176.05
Price/Earnings
UCBJF
EXEL
JAZZ

Financial Strength

Metric
UCBJF
EXEL
JAZZ
Quick Ratio
0.843.131.52
Current Ratio
1.323.342.24
Interest Coverage
3.882.03
Quick Ratio
UCBJF
EXEL
JAZZ

Profitability

Metric
UCBJF
EXEL
JAZZ
Return on Assets (Normalized)
5.10%9.47%11.62%
Return on Equity (Normalized)
8.82%11.88%37.73%
Return on Invested Capital (Normalized)
7.41%8.36%16.77%
Return on Assets
UCBJF
EXEL
JAZZ
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRQzccywskgFksy$557.8 Bil
VRTX
Vertex Pharmaceuticals IncMvdbxdqdXgnxnv$103.3 Bil
REGN
Regeneron Pharmaceuticals IncGnlttwcglNcxchj$98.8 Bil
MRNA
Moderna IncXjscgtfdjPqxv$38.8 Bil
ARGX
argenx SE ADRJdplskskrVmq$21.3 Bil
BNTX
BioNTech SE ADRPvrjfmxdHnsl$20.8 Bil
ALNY
Alnylam Pharmaceuticals IncSvxnrlkshGsrxh$18.4 Bil
BMRN
Biomarin Pharmaceutical IncZvpvghrkTnbzyg$17.0 Bil
RPRX
Royalty Pharma PLC Class ATjyskfpdpPsknyq$12.4 Bil
INCY
Incyte CorpDhzndvwkTyjvsq$11.9 Bil

Sponsor Center